151 related articles for article (PubMed ID: 10213207)
1. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging.
Rosenthal DI; Nurenberg P; Becerra CR; Frenkel EP; Carbone DP; Lum BL; Miller R; Engel J; Young S; Miles D; Renschler MF
Clin Cancer Res; 1999 Apr; 5(4):739-45. PubMed ID: 10213207
[TBL] [Abstract][Full Text] [Related]
2. Gd-Tex Pharmacyclics Inc.
Radford IR
Curr Opin Investig Drugs; 2000 Dec; 1(4):524-8. PubMed ID: 11249709
[TBL] [Abstract][Full Text] [Related]
3. Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent.
Bernhard EJ; Mitchell JB; Deen D; Cardell M; Rosenthal DI; Brown JM
Cancer Res; 2000 Jan; 60(1):86-91. PubMed ID: 10646858
[TBL] [Abstract][Full Text] [Related]
4. In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer.
Miller RA; Woodburn K; Fan Q; Renschler MF; Sessler JL; Koutcher JA
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):981-9. PubMed ID: 10571206
[TBL] [Abstract][Full Text] [Related]
5. Reversible renal toxicity resulting from high single doses of the new radiosensitizer gadolinium texaphyrin.
Rosenthal DI; Becerra CR; Toto RD; Carbone DP; Frenkel EP
Am J Clin Oncol; 2000 Dec; 23(6):593-8. PubMed ID: 11202804
[TBL] [Abstract][Full Text] [Related]
6. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases.
Viala J; Vanel D; Meingan P; Lartigau E; Carde P; Renschler M
Radiology; 1999 Sep; 212(3):755-9. PubMed ID: 10478243
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).
van Laarhoven HW; Fiedler W; Desar IM; van Asten JJ; Marréaud S; Lacombe D; Govaerts AS; Bogaerts J; Lasch P; Timmer-Bonte JN; Lambiase A; Bordignon C; Punt CJ; Heerschap A; van Herpen CM
Clin Cancer Res; 2010 Feb; 16(4):1315-23. PubMed ID: 20145168
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases.
Carde P; Timmerman R; Mehta MP; Koprowski CD; Ford J; Tishler RB; Miles D; Miller RA; Renschler MF
J Clin Oncol; 2001 Apr; 19(7):2074-83. PubMed ID: 11283141
[TBL] [Abstract][Full Text] [Related]
10. Motexafin gadolinium: gadolinium (III) texaphyrin, gadolinium texaphyrin, Gd-Tex, GdT2B2, PCI 0120.
Drugs R D; 2004; 5(1):52-7. PubMed ID: 14725495
[TBL] [Abstract][Full Text] [Related]
11. A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G; Siu LL; Gauthier I; Chen EX; Oza AM; Goel R; Maroun J; Powers J; Walsh W; Maclean M; Drolet DW; Rusk J; Seymour LK;
Cancer Chemother Pharmacol; 2006 Nov; 58(5):703-10. PubMed ID: 16528532
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
[TBL] [Abstract][Full Text] [Related]
13. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
14. Motexafin gadolinium: a novel radiosensitizer for brain tumors.
Francis D; Richards GM; Forouzannia A; Mehta MP; Khuntia D
Expert Opin Pharmacother; 2009 Sep; 10(13):2171-80. PubMed ID: 19640206
[TBL] [Abstract][Full Text] [Related]
15. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.
Khuntia D; Mehta M
Expert Rev Anticancer Ther; 2004 Dec; 4(6):981-9. PubMed ID: 15606327
[TBL] [Abstract][Full Text] [Related]
16. Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome.
Mirsalis JC; Schindler-Horvat J; Hill JR; Green CE; Mitoma C; Tomaszewski JE; Tyson CA; Donohue SJ
Cancer Chemother Pharmacol; 2003 Mar; 51(3):193-201. PubMed ID: 12655436
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
19. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
